Experimental drug shows promise for early Alzheimer’s

Key Points

A new experimental drug, diranersen, shows potential in slowing early Alzheimer's by targeting tau protein.
The study of 400 people suggests the drug lowers tau levels and may slow cognitive decline.
This approach differs from current treatments like lecanemab that primarily target amyloid plaques.
Researchers are planning larger trials to verify these early findings and assess long-term safety.

Background History

Alzheimer's disease is a progressive brain disorder affecting millions worldwide, characterized by the accumulation of amyloid plaques and tau tangles. While recent years have seen the approval of amyloid-clearing drugs like lecanemab and donanemab, the search for treatments targeting other biological mechanisms, such as tau, remains a critical priority for researchers.

Researchers have reported encouraging results from an early-stage clinical trial of a new experimental drug designed to treat Alzheimer’s disease. The study, presented this week at the Alzheimer’s Association International Conference in London, suggests the drug may help slow cognitive decline by targeting a brain protein called tau. This approach marks a potential shift in strategy, as most currently available treatments focus primarily on clearing a different protein known as amyloid.

Alzheimer’s disease is a progressive condition that gradually destroys memory and thinking skills. While the exact causes remain a subject of intense scientific study, the disease is characterized by the buildup of toxic proteins in the brain, including both amyloid plaques and tau tangles. These changes lead to the loss of neurons and the connections between them, eventually impairing a person's ability to perform daily tasks.

In the new study involving approximately 400 participants, the drug, known as diranersen and developed by Biogen, demonstrated an ability to lower tau levels in the brain. Beyond this biological marker, researchers observed signs that the treatment also slowed cognitive decline. In a small subset of the study group, the observed benefits were described as comparable to those seen with existing amyloid-targeting therapies.

While these findings are considered a positive development, experts emphasize that the research is still in its early stages. Previous attempts by various pharmaceutical companies to develop drugs targeting tau have faced significant challenges and often failed to produce clinical benefits. The research team is now planning a larger, more comprehensive study to confirm these initial results and better understand the drug's safety and effectiveness.

For the millions of people living with Alzheimer’s, these results offer a glimmer of hope for future treatment options. However, the medical community maintains a cautious outlook, noting that it will take time to determine if this drug can provide a meaningful, long-term benefit for patients. The focus remains on continuing rigorous testing to ensure that any new therapy is both safe and effective before it can be considered for wider use.